FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience
Anti-Cancer Drugs, 08/23/2013Moretto R et al.
The aim of this study was to evaluate the toxicity and the activity of the FOLFIRI regimen as first–line or second–line chemotherapy in patients with pancreatic or biliary tract tumors. The median overall survival rates were 14.5 months (95% CI, 7.0–22.1) and 6.2 months (95% CI, 5.4–7.0), respectively, in the first–line and the second–line cohort of patients. FOLFIRI is feasible and well tolerated in patients with pancreatic or biliary tract tumors; it has a good activity in first line and mostly in patients with pancreatic cancer.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.